{
    "id": 1214,
    "fullName": "NF1 mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "NF1 mutant indicates an unspecified mutation in the NF1 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 4763,
        "geneSymbol": "NF1",
        "terms": [
            "NF1",
            "NFNS",
            "VRNF",
            "WSS"
        ]
    },
    "variant": "mutant",
    "createDate": "07/30/2014",
    "updateDate": "08/28/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14031,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Chinese metastatic colorectal cancer patients harboring a NF1 mutation did not respond to treatment with Erbitux (cetuximab) and showed a shorter progression-free survival compared to patients with wild-type NF1 (median: 53.5 vs 211 days, p=0.0028) (PMID: 29703253).",
            "molecularProfile": {
                "id": 1239,
                "profileName": "NF1 mutant"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11426,
                    "pubMedId": 29703253,
                    "title": "SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29703253"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18502,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Selumetinib (AZD6244) treatment resulted in a sustained partial response (PR) in 36% (9/25) and stable disease in 60% (15/25) of pediatric patients with NF1-associated low grade glioma, with a 2-year progression-free survival of 96% (PMID: 31151904; NCT01089101).",
            "molecularProfile": {
                "id": 1239,
                "profileName": "NF1 mutant"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 60108,
                "name": "brain glioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16287,
                    "pubMedId": 31151904,
                    "title": "Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31151904"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6720,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a clinical analysis, NF1 mutations are associated with higher mutational load and better response rate to anti-programmed death-1/ligand treatments in melanoma patients (J Clin Oncol 34, 2016 (suppl; abstr 105)).",
            "molecularProfile": {
                "id": 1239,
                "profileName": "NF1 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5782,
                    "pubMedId": null,
                    "title": "Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1.",
                    "url": "http://abstracts.asco.org/176/AbstView_176_163406.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3803,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SBI-0640756 inhibited growth and transformation of human melanomas cells harboring NF1 mutations (PMID: 26603897).",
            "molecularProfile": {
                "id": 1239,
                "profileName": "NF1 mutant"
            },
            "therapy": {
                "id": 3306,
                "therapyName": "SBI-0640756",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4137,
                    "pubMedId": 26603897,
                    "title": "SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603897"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1239,
            "profileName": "NF1 mutant",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}